Clinical Trial Update: Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 [Phase 3]

View source ↗

Summary

Phase 3 trial update on safety and tolerability of the Japanese Encephalitis vaccine IC51 (Valneva).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IC51

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2012-11-20